TUBERCULOSIS DRUGS MARKET ANALYSIS

Tuberculosis Drugs Market, by Therapy Type (First Line Therapy, and Second Line Therapy), by Disease type (Active TB, and Latent TB), by End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2019 – 2027

Published In : Sep 2019
Code : CMI191
Pages :198
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Tuberculosis Drugs Market – Restraints

The increasing incidence of drug recall is a major factor restraining the market growth. Manufacturers of TB drug are facing challenges such as increasing product recalls owing to factors such as packaging or manufacturing flaws. For instance, in 2018, Sandoz recalled its batch of wrongly-packed tuberculosis (TB) drugs in India. Furthermore, in 2016, Novartis manufactured a drug Onecure which was recalled by the Philippines Food and Drug Administration for insufficient amount of rifampicin in the drug.

The high pricing of drugs is another factor restraining the growth of the market. Second line treatment drugs are highly priced compared to first line treatment with more side effects and high level toxicity.

Tuberculosis Drugs Market Report Snapshots